Skip to main content
logo
CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.1288
0.00 (0.00%)
At close: Aug 31, 2026

CASI Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
20.1120.7128.5433.8843.1130.17
Revenue Growth
-36.28%-27.42%-15.77%-21.41%42.89%99.25%
Gross Profit
12.0610.0811.1520.0527.2817.61
Operating Income
-38.34-42.85-39.21-25.28-26.49-35.22
Net Income
-43.97-48.06-39.26-26.96-41.01-36.65
Earnings Per Share
-2.09-2.59-2.56-2.02-3.01-2.69
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3.775.6316.0930.7751.3448.57
Total Debt
40.527.4922.1421.241.342.17
Net Cash (Debt)
-36.73-21.85-6.059.5349.9946.41
Net Cash Growth
----80.94%7.73%-26.55%
Net Cash Per Share
-1.74-1.18-0.390.713.663.41

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
--20.75-29.22-19.97-21.09-26.84
Capital Expenditures
--0.02-0.22-0.2-5.61-8.95
Free Cash Flow
--20.77-29.45-20.17-26.7-35.79
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
59.97%48.65%39.06%59.19%63.28%58.38%
Operating Margin
-190.59%-206.87%-137.41%-74.62%-61.45%-116.74%
Pretax Margin
-218.58%-232.03%-137.57%-77.75%-88.80%-118.81%
Profit Margin
-218.58%-232.03%-137.57%-79.58%-95.14%-121.50%
FCF Margin
--100.28%-103.19%-59.54%-61.94%-118.63%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-37.2937.29---
PS Ratio
0.130.841.542.820.563.71